Dapiprazole: Difference between revisions
m (Protected "Dapiprazole": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
No edit summary |
||
(One intermediate revision by the same user not shown) | |||
Line 1: | Line 1: | ||
{{Drugbox | {{Drugbox | ||
| IUPAC_name | | Verifiedfields = changed | ||
| image | | verifiedrevid = 460112976 | ||
| IUPAC_name = 3-{2-[4-(2-methylphenyl)piperazin-1-yl]ethyl}-5,6,7,8-<br>tetrahydro-[1,2,4]triazolo[4,5-''a'']pyridine | |||
| image = Dapiprazole.png | |||
<!--Clinical data--> | |||
| tradename = | |||
| Drugs.com = {{drugs.com|CDI|dapiprazole}} | |||
| MedlinePlus = a601043 | |||
| pregnancy_category = B | |||
| legal_status = Rx-only | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| routes_of_administration = Topical ([[eye drops]]) | | routes_of_administration = Topical ([[eye drops]]) | ||
<!--Pharmacokinetic data--> | |||
| bioavailability = Negligible when administered topically | |||
| elimination_half-life = | |||
| excretion = | |||
<!--Identifiers--> | |||
| CASNo_Ref = {{cascite|correct|CAS}} | |||
| CAS_number_Ref = {{cascite|correct|??}} | |||
| CAS_number = 72822-12-9 | |||
| ATC_prefix = S01 | |||
| ATC_suffix = EX02 | |||
| PubChem = 3033538 | |||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} | |||
| DrugBank = DB00298 | |||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | |||
| ChemSpiderID = 2298190 | |||
| UNII_Ref = {{fdacite|correct|FDA}} | |||
| UNII = 5RNZ8GJO7K | |||
| KEGG_Ref = {{keggcite|correct|kegg}} | |||
| KEGG = D07775 | |||
| ChEBI_Ref = {{ebicite|correct|EBI}} | |||
| ChEBI = 51066 | |||
| ChEMBL_Ref = {{ebicite|changed|EBI}} | |||
| ChEMBL = 1201216 | |||
<!--Chemical data--> | |||
| C=19 | H=27 | N=5 | |||
| molecular_weight = 325.451 g/mol | |||
| smiles = n1nc(n2c1CCCC2)CCN4CCN(c3ccccc3C)CC4 | |||
| InChI = 1/C19H27N5/c1-16-6-2-3-7-17(16)23-14-12-22(13-15-23)11-9-19-21-20-18-8-4-5-10-24(18)19/h2-3,6-7H,4-5,8-15H2,1H3 | |||
| InChIKey = RFWZESUMWJKKRN-UHFFFAOYAD | |||
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} | |||
| StdInChI = 1S/C19H27N5/c1-16-6-2-3-7-17(16)23-14-12-22(13-15-23)11-9-19-21-20-18-8-4-5-10-24(18)19/h2-3,6-7H,4-5,8-15H2,1H3 | |||
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | |||
| StdInChIKey = RFWZESUMWJKKRN-UHFFFAOYSA-N | |||
}} | }} | ||
'''Dapiprazole''' ( | __NOTOC__ | ||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Dapiprazole''' ('''Rev-Eyes''') is an [[alpha blocker]]. It is used to reverse [[mydriasis]] after [[eye examination]].<ref>{{cite journal |title = A Review of the Clinical Pharmacokinetics of Pilocarpine, Moxisylyte (Thymoxamine), and Dapiprazole in the Reversal of Diagnostic Pupillary Dilation |author = Doughty, Michael J.; Lyle, William M. |journal = Optometry & Vision Science |date = May 1992 |volume = 69 |issue = 5 |url = http://journals.lww.com/optvissci/Abstract/1992/05000/A_Review_of_the_Clinical_Pharmacokinetics_of.5.aspx}}</ref> | |||
== References == | |||
{{Reflist|2}} | |||
{{Antiglaucoma preparations and miotics}} | {{Antiglaucoma preparations and miotics}} | ||
[[Category:Alpha blockers]] | [[Category:Alpha blockers]] | ||
[[Category:Piperazines]] | |||
[[Category:Drug]] |
Latest revision as of 14:53, 10 April 2015
Clinical data | |
---|---|
AHFS/Drugs.com | Consumer Drug Information |
MedlinePlus | a601043 |
Pregnancy category |
|
Routes of administration | Topical (eye drops) |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | Negligible when administered topically |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C19H27N5 |
Molar mass | 325.451 g/mol |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
WikiDoc Resources for Dapiprazole |
Articles |
---|
Most recent articles on Dapiprazole Most cited articles on Dapiprazole |
Media |
Powerpoint slides on Dapiprazole |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Dapiprazole at Clinical Trials.gov Clinical Trials on Dapiprazole at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Dapiprazole
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Dapiprazole Discussion groups on Dapiprazole Patient Handouts on Dapiprazole Directions to Hospitals Treating Dapiprazole Risk calculators and risk factors for Dapiprazole
|
Healthcare Provider Resources |
Causes & Risk Factors for Dapiprazole |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Dapiprazole (Rev-Eyes) is an alpha blocker. It is used to reverse mydriasis after eye examination.[1]
References
- ↑ Doughty, Michael J.; Lyle, William M. (May 1992). "A Review of the Clinical Pharmacokinetics of Pilocarpine, Moxisylyte (Thymoxamine), and Dapiprazole in the Reversal of Diagnostic Pupillary Dilation". Optometry & Vision Science. 69 (5).
- Pages with script errors
- CS1 maint: Multiple names: authors list
- Template:drugs.com link with non-standard subpage
- Drugs with non-standard legal status
- Articles with changed EBI identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Drugboxes which contain changes to verified fields
- Alpha blockers
- Piperazines
- Drug